HSKA · Heska Corp - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Annual Quarterly

Income Statement

Line item	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Revenue	$257.31M	$253.74M	$197.32M	-	-	$129.34M
Cost of Revenue	$146.14M	$147.94M	$116.03M	$68.21M	$70.81M	$71.08M
Gross Profit	$111.17M	$105.79M	$81.29M	$54.45M	$56.64M	$58.26M
R&D	$19.75M	$6.98M	$8.77M	$8.24M	$3.33M	$2.00M
SG&A	$64.05M	$54.52M	$42.24M	$18.20M	$24.85M	$14.81M
Total Operating Expenses	$131.47M	$106.79M	$89.48M	$54.12M	$52.84M	$40.04M
D&A	$13.97M	$13.55M	$11.38M	$4.92M	$4.59M	$4.75M
Operating Income	($20.30M)	($993.0K)	($8.19M)	$327.0K	$3.79M	$18.22M
Interest Expense	$4.19M	$4.20M	$6.37M	$3.09M	$310.0K	$245.0K
Income Tax	($3.41M)	($3.57M)	$239.0K	($1.45M)	($2.12M)	$8.91M
Net Income	($19.89M)	($1.15M)	($14.40M)	($1.47M)	$5.85M	$9.95M
EPS - Basic	($1.92)	($0.11)	($1.66)	($0.20)	$0.81	$1.42
EPS - Diluted	($1.92)	($0.11)	($1.66)	($0.20)	$0.74	$1.30

Balance Sheet

Line item	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Cash & Equivalents	$156.62M	$223.57M	$86.33M	$89.03M	$13.39M	$9.66M
Accounts Receivable	$29.49M	$28.00M	$31.08M	$15.16M	$16.45M	$15.71M
Inventory	$60.05M	$49.36M	$40.04M	$26.60M	$25.10M	$32.60M
Accounts Payable	$16.40M	$15.37M	$15.12M	$6.60M	$7.47M	$9.49M
Current Assets	$265.03M	$319.56M	$171.28M	$139.87M	$62.41M	$62.91M
Total Assets	$585.82M	$604.07M	$399.84M	$244.42M	$156.45M	$135.79M
Current Liabilities	$39.58M	$43.93M	$42.12M	$32.20M	$20.36M	$25.73M
Long-term Debt	-	-	-	$1.12M	$6.00M	-
Total Liabilities	$163.61M	$168.22M	$112.79M	$89.89M	$34.04M	$35.35M
Stockholders' Equity	$422.21M	$435.85M	$287.05M	$154.36M	$122.41M	$100.44M
Retained Earnings	($168.53M)	($148.64M)	($150.86M)	($136.44M)	($134.98M)	($143.46M)

Cash Flow

Line item	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Operating Cash Flow	($21.81M)	$6.25M	($656.0K)	$3.30M	$13.29M	$10.41M
Investing Cash Flow	($35.77M)	($35.00M)	($126.60M)	($1.92M)	($12.17M)	($17.17M)
Financing Cash Flow	($7.05M)	$166.40M	$123.76M	$74.26M	$2.63M	$5.55M
CapEx	-	-	-	$1.04M	$1.36M	$3.47M
Free Cash Flow	-	-	-	$2.25M	$11.93M	$6.94M

Ratios

Metric	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Profitability
Gross margin	43.2%	41.7%	41.2%	-	-	45.0%
Operating margin	-7.9%	-0.4%	-4.2%	-	-	14.1%
EBITDA margin	-2.5%	5.0%	1.6%	-	-	17.8%
Net margin	-7.7%	-0.5%	-7.3%	-	-	7.7%
Free cash flow margin	-	-	-	-	-	5.4%
FCF / Net income	-	-	-	-1.54	2.04	0.70
R&D / Revenue	7.7%	2.8%	4.4%	-	-	1.5%
SG&A / Revenue	24.9%	21.5%	21.4%	-	-	11.5%
Effective tax rate	-	-	-	-	-56.6%	47.2%
Return on assets	-3.4%	-0.2%	-3.6%	-0.6%	3.7%	7.3%
Return on equity	-4.7%	-0.3%	-5.0%	-0.9%	4.8%	9.9%
Return on invested capital	-	-	-	0.2%	3.0%	-
Liquidity
Current ratio	6.70	7.27	4.07	4.34	3.06	2.45
Quick ratio	5.18	6.15	3.12	3.52	1.83	1.18
Cash ratio	3.96	5.09	2.05	2.76	0.66	0.38
Leverage
Debt / Equity	-	-	-	0.01	0.05	-
Debt / Assets	-	-	-	0.00	0.04	-
Debt / EBITDA	-	-	-	0.21	0.72	-
Interest coverage	-4.8x	-0.2x	-1.3x	0.1x	12.2x	74.4x
Equity multiplier	1.39	1.39	1.39	1.58	1.28	1.35
Liabilities / Assets	0.28	0.28	0.28	0.37	0.22	0.26
Efficiency
Asset turnover	0.44	0.42	0.49	-	-	0.95
Inventory turnover	2.43	3.00	2.90	2.56	2.82	2.18
Days sales outstanding	42d	40d	57d	-	-	44d
Days inventory outstanding	150d	122d	126d	142d	129d	167d
Days payable outstanding	41d	38d	48d	35d	39d	49d
Cash conversion cycle	151d	124d	136d	-	-	163d
Valuation
P / E	-	-	-	-	-	-
P / B	-	-	-	-	-	-
P / S	-	-	-	-	-	-
EV / EBITDA	-	-	-	-	-	-
Growth
Revenue growth (YoY)	1.4%	28.6%	-	-	-	-0.6%
Revenue CAGR (3y)	-	-	15.1%	-	-	12.9%
Revenue CAGR (5y)	14.7%	14.3%	13.5%	-	-	12.2%
Gross profit growth (YoY)	5.1%	30.1%	49.3%	-3.9%	-2.8%	8.1%
Operating income growth (YoY)	-1944.1%	87.9%	-	-91.4%	-79.2%	10.2%
Net income growth (YoY)	-1632.5%	92.0%	-882.9%	-	-41.2%	-5.3%
EPS growth (YoY)	-1645.5%	93.4%	-730.0%	-	-43.1%	-9.1%
EPS CAGR (3y)	-	-	-	-	0.0%	46.9%
EPS CAGR (5y)	-	-	-	-	-	42.7%
FCF growth (YoY)	-	-	-	-81.1%	71.9%	184.7%
FCF CAGR (5y)	-	-	-	-8.2%	-	-
Book value growth (YoY)	-3.1%	51.8%	86.0%	26.1%	21.9%	15.5%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2021-12-31.

Business segments

$253.74M total

North America Segment$158.90M · 62.6%

International Segment$94.84M · 37.4%

Product / service

$158.90M total

Point Of Care Laboratory Revenue Consumables$72.00M · 45.3%

Point Of Care Laboratory Revenue Imaging$29.51M · 18.6%

Other Revenue Other Pharmaceuticals Vaccines And Diagnostic Tests$24.94M · 15.7%

OVP$17.61M · 11.1%

Point Of Care Laboratory Revenue Lab Instruments And Other$14.84M · 9.3%

Geographic

$253.74M total

US$141.59M · 55.8%

DE$44.15M · 17.4%

FR$18.67M · 7.4%

CA$17.31M · 6.8%

ES$14.07M · 5.5%

IT$10.14M · 4.0%

Other International$3.92M · 1.5%

CH$3.88M · 1.5%

Stability scores

Altman Z′

FY 2022 · bankruptcy risk

1.45

Grey zone

Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.

Piotroski F-score

FY 2022 · 9-point quality

2/9

Weak

✗Net income positive
✗Operating cash flow positive
✗ROA improved YoY
✗Cash flow > net income
-Long-term debt decreased
✗Current ratio improved
✗No share dilution
✓Gross margin improved
✓Asset turnover improved

Peer comparison

Same SIC group: In Vitro & In Vivo Diagnostic Substances

Company	Revenue (last FY)	Net margin	ROE
VNRX	$1.73M	-1352.2%	68.2%
QDEL	$2.73B	-41.5%	-58.9%
MYGN	$824.50M	-44.4%	-99.4%
LNTH	$1.54B	15.2%	21.4%
IDXX	$4.30B	24.6%	66.0%

Comparing HESKA CORP against the 5 most active filers in the same SIC group.